ADC Therapeutics (ADCT) Retained Earnings (2019 - 2026)
ADC Therapeutics (ADCT) posted Retained Earnings of -$1.7 billion for Q1 2026, down 2.02% sequentially from -$1.6 billion in Q4 2025, and down 8.94% YoY from -$1.8 billion in Q1 2025.
ADC Therapeutics (ADCT) Retained Earnings (2019 - 2026) Analysis & Trends
ADC Therapeutics has reported Retained Earnings for 8 years, with the latest figure at -$1.7 billion in Q1 2026.
- Quarterly Retained Earnings fell 8.94% year-over-year to -$1.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.7 billion (down 8.94% YoY) and the FY2025 annual result came in at -$1.6 billion, down 9.55% from the prior year.
- Retained Earnings fell to -$1.7 billion in Q1 2026 per ADCT's latest filing, from -$1.6 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $1.2 billion in Q4 2022 and troughed at -$1.7 billion in Q1 2026.
- A 5-year average of -$1.2 billion and a median of -$1.4 billion in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings soared 226.11% in 2022, then tumbled 214.49% in 2023.
- Over 5 years, Retained Earnings stood at $1.2 billion in 2022, then sank by 214.49% to -$1.3 billion in 2023, then slipped by 11.82% to -$1.5 billion in 2024, then declined by 9.55% to -$1.6 billion in 2025, then fell by 2.02% to -$1.7 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$1.7 billion, -$1.6 billion, and -$1.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.96 Bn | 132.11 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 60.20 Bn | 55.06 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.19 Bn | 37.09 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.43 Bn | 28.12 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 4.38 Bn |
| 10 | ADC Therapeutics | 154.54 Mn | -64.57 Mn | 17.14 Mn | -1.69 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.69 Bn |
| Mar 31, 2026 | -1.67 Bn |
| Dec 31, 2025 | -1.64 Bn |
| Sep 30, 2025 | -1.63 Bn |
| Jun 30, 2025 | -1.59 Bn |
| Mar 31, 2025 | -1.53 Bn |
| Dec 31, 2024 | -1.49 Bn |
| Sep 30, 2024 | -1.46 Bn |
| Jun 30, 2024 | -1.42 Bn |
| Mar 31, 2024 | -1.38 Bn |
| Dec 31, 2023 | -1.34 Bn |
| Sep 30, 2023 | -1.24 Bn |
| Jun 30, 2023 | -1.19 Bn |
| Mar 31, 2023 | -1.14 Bn |
| Dec 31, 2022 | 1.17 Bn |
| Sep 30, 2022 | -1.06 Bn |
| Jun 30, 2022 | -1.01 Bn |
| Mar 31, 2022 | -941.55 Mn |
| Dec 31, 2021 | -924.89 Mn |
| Sep 30, 2021 | -890.50 Mn |